SCHEMBL5147930

SCHEMBL5147930

CCn1nc(-c2ncc(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
HTT P42858 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
USP2 O75604 1/20 0.38
TNNI3 P19429 1/20 0.38
CRHBP P24387 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
TNNT2 P45379 1/20 0.38
CASP7 P55210 1/20 0.38
TNNC1 P63316 1/20 0.38
ATM Q13315 1/20 0.38
CRHR2 Q13324 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149060 0.84 ADORA2A (0.45) ADORA2AADORA1HTTKDM4ESMN1; SMN2
SCHEMBL27659527 0.82 HTT (0.47) ADORA1HTTMEN1KMT2AHSD17B10
SCHEMBL5149067 0.81 ADORA2A (0.49) ADORA2AADORA1TP53POLB
SCHEMBL6133923 0.80 ADORA1 (0.47) ADORA2AADORA1HTT
SCHEMBL5152435 0.77 USP8 (0.43) ADORA2AADORA1HTTMEN1KMT2A
SCHEMBL5149222 0.77 HTT (0.44) ADORA2AHTTMEN1KMT2AHSD17B10
SCHEMBL4054492 0.77 HTT (0.62) HTTMEN1KMT2AHSD17B10KDM4E
SCHEMBL5147969 0.77 HTT (0.43) ADORA1HTTMEN1KMT2AHSD17B10
SCHEMBL5147924 0.77 ADORA2A (0.49) ADORA2AADORA1TP53POLB
SCHEMBL6134833 0.76 ALDH1A1 (0.51) ADORA1HTTMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US claimed
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 ADORA2A 1/4885ADORA1 3/4885HTT 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.